Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, distributes pharmaceutical products in China. It operates through Pharmaceutical Distribution; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails pharmaceutical products through hospitals, clinics, other medical institutions, pharmacies, health centers, clinics, directly operated stores, general agents, distributors, and allocations. It also provides pearl eye drops, pearl powder, and pearl layer powder under the Haibao brand; brand gastrointestinal granules, honeysuckle oral solution, and children's syrup under the Guofa brand; and traumatic injury medicated wine, and sea snake medicated wine under the Haima brand. In addition, the company produces and sells forensic DNA testing equipment, reagents, and consumables; and provides technical services, including DNA testing services. Further, it engages in culture and arts activities; and provision of technical services. The company was formerly known as Beihai Gofar Marine Biological Industry Co., Ltd. and changed its name to Beihai Gofar Chuanshan Biological Co., Ltd. in June 2021. Beihai Gofar Chuanshan Biological Co., Ltd. was incorporated in 1993 and is headquartered in Beihai, China.
Research context
Beihai Gofar Chuanshan Biological Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Beihai Gofar Marine Biological Industry Co., Ltd is currently in a long term uptrend where the price is trading 9.1% above its 200 day moving average.
From a valuation standpoint, the stock is 328.4% more expensive than other stocks from the Basic Materials sector with a price to sales ratio of 17.2.
Beihai Gofar Marine Biological Industry Co., Ltd's total revenue sank by 10.1% to $64M since the same quarter in the previous year.
Its net income has dropped by 8.2% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 107.2% to $546K since the same quarter in the previous year.
Based on the above factors, Beihai Gofar Marine Biological Industry Co., Ltd gets an overall score of 2/5.